The PRWIRE Press Releases https:// 2019-03-14T00:39:19Z US expert presents evidence for innovative drug-free pain management device, ActiPatch® 2019-03-14T00:39:19Z us-expert-presents-evidence-for-innovative-drug-free-pain-management-device-actipatch-r Mundipharma was pleased to welcome Biomedical Engineer Dr Sree Koneru to Australia to give a presentation on the innovative pain management device, ActiPatch®, which he helped develop. ActiPatch® uses electromagnetic pulse therapy to provide long-lasting pain relief. Dr Koneru is the Vice President of Product Development for Bioelectronics and visited Australia to present the clinical evidence behind ActiPatch® at the Australian Pharmacy Conference on the Gold Coast. You can watch Dr Koneru discussing ActiPatch® on Chanel Seven’s Weekend Sunrise here. “The new understanding of chronic pain is that nerves ‘memorise’ the initial pain from injury and over time, become hyperreactive,” Dr Koneru said. “When used over a painful area, ActiPatch’s pulsed signal is absorbed by tissue and disrupts hyperactivity of the nerves, resulting in lasting relief.” Electromagnetic pulse therapy helps to relieve pain from mild osteoarthritis and general musculoskeletal pain in the back, knee, heel and other muscle joints. It is also ideal for strains, sprains and other painful conditions. The therapy is completely sensation free, with no heat, tingling sensations or vibration. ActiPatch® is drug-free and can be safely used with any other medications. A registry studyi of more than 5,000 chronic pain sufferers using ActiPatch® indicated that: • More than 65% per cent reported a clinically meaningful reduction in pain from a wide variety of causes and locations of pain • The average pain reduction reported in these individuals was 57% • The 3-month follow-up showed sustained pain relief, decreased oral analgesic medication use and quality of life improvement. “ActiPatch® uses low-level therapy to allow 24/7 use and, as it doesn’t require skin contact, can be used over bandages and clothing,” said Dr Koneru. “Can also be used by people with metallic implants and when not placed directly over them, electronic devices such as pacemakers/defibrillators.” Mundipharma recently acquired the exclusive Australian and New Zealand distribution rights for ActiPatch®, reinforcing its commitment to the multimodal approach to pain management. This multimodal approach includes cognitive behavioural therapies, physical therapies and pharmacological therapies. “Mundipharma has worked collaboratively with healthcare professionals to provide appropriate access to pain relief over the past 20 years,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “Our work with leading clinicians and reputation as a trusted medical advisor will enable us to help more patients benefit from this therapy.” The results of clinical trials involving ActiPatch® can be found here. Always read the label. Follow the directions for use. If symptoms persist, see your healthcare professional. Further information is available from Mundipharma Pty Limited, 88 Phillip Street, Sydney, NSW 2000. Phone 1800 188 009 or email medinfo@mundipharma.com.au. For media enquiries, please contact: Rob Bates Communications Manager +61 422 196 238 Rob.Bates@mundipharma.com.au About Mundipharma Mundipharma is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold. For more information, please visit: www.mundipharma.com.au. ® ACTIPATCH is a registered trademark. References i Rawe et al. Pain Manag. 5(6):413-423 (2015) Pharma veterans guide next generation of researchers and entrepreneurs 2018-11-12T23:36:44Z pharma-veterans-guide-next-generation-of-researchers-and-entrepreneurs Pharmaceutical sector leaders and experts joined government and NGO representatives to share their collective wisdom with young researchers, entrepreneurs and industry professionals at The Bridge Program’s Residential Training Program last week. The Bridge Program was launched in 2017 to boost the commercial output of Australian pharmaceutical research by providing face-to-face and online training in research translation and the commercialisation of medicines. Run by Queensland University of Technology, it involves a consortium of 15 pharmaceutical companies, universities and industry associations, and selects 100 participants from across Australia annually. The three-day Residential Training Program, now in its second year, involved workshops, case studies, networking opportunities and presentations from national and international guests, including CEO of Innovation and Science Australia, Charlie Day, Amgen’s VP of Global Health Economics, Martin Zagari, and Member for Bennelong John Alexander MP, to name a few. Mr Zagari presented on the value of medicines in healthcare and society, which he said was being challenged by a shift in focus from value to cost. He said fixating on initial investment costs was misleading, as almost all investments in medicines became cost neutral and most became cost saving, yielding enormous value. “In the US, every dollar spent on medicines for congenital heart failure returned $3-$10 in savings,” he said. “Every 1% reduction in cancer mortality would deliver $500 billion in savings globally. We need to consider what the cost of not improving treatments will be.” Mundipharma’s Director of Corporate Affairs, Meriana Baxter, chaired a session that tasked cross-functional teams with delivering a mock pitch to industry executives role-playing as venture capital investors. The “investors” were impressed with what the teams achieved in a short timeframe, but provided detailed advice on how they could cut through more effectively. My Linh Kha, Executive Director and General Manager of Amgen Australia and New Zealand, spoke of the promise of the medical discoveries that may be made by the attendees, and the benefits they may have on patients in the future. “I am so proud of the collective knowledge and experience that can be leveraged through this program,” Ms Kha said. “I wish an opportunity like this existed when I began my career, and I am sure we’ll be seeing the impact of this effort for years and decades to come.” Mr Alexander closed the program with a reflection on his time representing his electorate and the home of “Pill Hill”. “I’m so lucky to have had the opportunity to meet so many in this industry,” Mr Alexander said. “You are all motivated by the common goal of improving quality of life, extending life and addressing illness.” The program’s final event for 2018 will be held at Queensland University of Technology on 13 December with keynote speaker Professor Ian Frazer, who co-invented the technology enabling human papilloma virus (HPV) vaccines. More information on The Bridge Program can be found here: research.qut.edu.au/bridge/, including a full agenda for the Residential Training Program. The Bridge Program collaborators include Mundipharma, MTPConnect, AbbVie, Amgen, The Australian Private Equity and Venture Capital Association Limited (AVCAL), Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Janssen-Cilag, Macquarie University, Medical Research Commercialisation Fund, Medicines Australia, MSD, Novartis and Pfizer. Mundipharma acquires product to help 1 million Australians with difficulty swallowing medication 2018-11-06T03:25:28Z mundipharma-acquires-product-to-help-1-million-australians-with-difficulty-swallowing-medication Mundipharma is proud to announce it has acquired the exclusive Australian and New Zealand distribution rights to the medication lubricant Gloup™, from Evomed Pty Limited (Evomed). Gloup™ is a medication lubricant that helps patients swallow tablets, capsules and powder medications more easily and is designed to have with minimal impact on medication absorption. More than 1 million Australians experience difficulty swallowingi, including 40-50 per cent of people living in aged care facilitiesii. Difficulty swallowing can develop at any stage of life and those at most risk include people taking multiple medications, anyone consuming large tablets, people with a dry mouth caused by medication or illness,children transitioning to tablets and oncology patients. It can also develop as a result of Parkinson’s disease, motor neuron disease, dementia and damage to the brain or structures of the head and neckiii. Crushing tablets or opening capsules can impact the effectiveness and risks associated with some medicationsiv and the Society of Hospital Pharmacists Australia’s Don’t Rush to Crush Handbook recommends the use of medication lubricantsv for patients with difficulty swallowing. Gloup™ is a slippery gel consisting of food based ingredients that have no known interactions with medications. Gloup™ is designed so that its ingredients break down almost immediately in the acidic environment of the stomach to minimise impact on medication absorption. “Mundipharma is a trusted source of information and education across primary care, hospital, aged care and retail pharmacy, so I am thrilled that Mundipharma will be able to help even more Australians benefit from this important product,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “Gloup™ addresses a serious need for many patients who are acutely unwell and may be in significant pain, making this aspect of their care so much easier and more comfortable.” This deal continues the growth and diversification of Mundipharma’s product portfolio, following this year’s launch of mundicare® Cold Defence, the securing of exclusive Australian and New Zealand distribution rights to PAINmate®, ActiPatch™ and AccuVein® – also from Evomed, as well as the acquisition of Tolmar Australia. This is in addition to the successful PBS listing of a medication for Peripheral T-Cell Lymphoma earlier this year. Mundipharma’s portfolio now includes 37 health care products across pain, oncology, ophthalmology, respiratory, first aid, hydration, the common cold, vein illumination technology and now, medication administration. Gloup™ is available in vanilla, orange, strawberry/banana, and low sugar cherry, and two levels of thickness, depending on the severity of swallowing difficulty. Always read the label. Use only as directed. If symptoms persist, see your healthcare professional Further information is available from Mundipharma Pty Limited, 88 Phillip Street, Sydney, NSW 2000. Phone 1800 188 009 or email medinfo@mundipharma.com.au. ® MUNDICARE is a registered trademark of MUNDIPHARMA. PAINMATE is a registered trademark. GLOUP is a trademark of Paxtree Limited. ACCUVEIN is a trademark of AccuVein Inc. ACTIPATCH is a trademark of BioElectronics Corporation. References i Speech Pathology Australia’s submission to Australian Government’s Department of Health: Electronic Health Records and Healthcare Identifiers: Legislation Discussion Paper. 24 June 2015. https://www.myhealthrecord.gov.au/sites/g/files/net5181/f/094_-_speech_pathology_australia.pdf?v=1526130629 ii https://www.racgp.org.au/download/documents/Guidelines/silverbook.pdf iii Speech Pathology Australia Fact Sheet: Swallowing. https://www.speechpathologyaustralia.org.au/spaweb/Document_Management/Public/Fact_Sheets.aspx#anchor_swal iv Australian Government Department of Health. Guiding principles for medication management in residential aged care facilities. http://www.health.gov.au/internet/main/publishing.nsf/content/guide-med-mgmt-aged-care. v The Society of Hospital Pharmacists Australia, 2015, Australian Don’t Rush to Crush Handbook, 2nd ed., p.21. AU-4857 MUNDIPHARMA SUPPORTS PIONEERING PROSTATE CANCER RESEARCH 2018-07-17T03:41:40Z mundipharma-supports-pioneering-prostate-cancer-research The 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has been awarded to Dr Kate Mahon, Medical Oncologist at Chris O’Brien Lifehouse, providing $60,000 to support her research into prostate cancer. This is the fifth annual Clinical Research Fellowship to be awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) to support genitourinary cancer research. The Fellowship was previously awarded by Tolmar Australia, which was acquired by Mundipharma in February, along with exclusive Australian and New Zealand distribution rights for prostate cancer medications Eligard® Injection and Bi Eligard® cp combination therapy. Dr Mahon was announced as the recipient of the Fellowship surrounded by experts in the research and treatment of genitourinary cancers at the 2018 ANZUP Annual Scientific Meeting in Sydney. “I am so pleased that Mundipharma was able to continue this significant support for research that will deliver real improvements in the treatment and management of prostate cancer,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. "Mundipharma is thrilled to be partnering with ANZUP to offer this Fellowship, which attracted a number of high quality applications from ANZUP’s multidisciplinary membership across Australia and from a range of institutions and professional groups.” "Dr Mahon is an accomplished researcher and I’m excited to see what can be achieved with this support.” Professor Ian Davis, Chair of ANZUP said Dr Mahon was a most deserving Fellowship recipient. “Dr Mahon’s project was a very strong one in an excellent field of applications. This is a novel approach to try to understand the behaviour of prostate cancer, which we hope might give better guidance for the treatment of these men in the future,” Professor Davis said. The Fellowship is intended for early and mid-career clinician-researchers of any health care discipline in genitourinary cancer research and provides funding for one year to the institution of the successful applicant. “Dr Mahon’s research is focussed on the search for biomarkers that will tell clinicians which drugs will be most effective for each patient ahead of time, and how their treatment should be sequenced,” Ms Orr said. “Ideally this will mean that a simple blood test could guide personalised prostate cancer therapy, helping clinicians give each individual patient the best possible chance.” Dr Mahon is a Movember Prostate Cancer Foundation of Australia Clinician Scientist Award recipient, with a post-doctoral research focus on the treatment of advanced prostate cancer. “The Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship will provide a fantastic opportunity to further my translational research goals, particularly in moving a blood-based biomarker into the clinic to directly help patients with advanced prostate cancer,” Dr Mahon said. Prostate cancer is the third most commonly diagnosed cancer in Australia, with one in seven men expected to be diagnosed before the age of 85. It is also the third most common cause of cancer death. About Mundipharma Mundipharma Pty Limited is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold. For more information please visit: www.mundipharma.com.au. For further information please contact: Rob Bates Communications Manager +61 422 196 238 Rob.Bates@mundipharma.com.au ® ELIGARD is a registered trademark. About ANZUP ANZUP is a cooperative cancer clinical trials group with over 1,300 members across Australia, New Zealand and internationally. ANZUP was established to bring together all the professional disciplines and groups involved in researching and treating urogenital cancers. ANZUP exists to conduct clinical trial research and to improve outcomes for people affected by these cancers. For information please visit: www.anzup.org.au For further information please contact: Michelle Bowers, Internal Communications Manager +61 415 098 485 michelle.bowers@anzup.org.au Mundipharma broadens pain portfolio with innovative physical therapy devices 2018-07-03T00:46:16Z mundipharma-broadens-pain-portfolio-with-innovative-physical-therapy-devices Mundipharma Pty Limited (Mundipharma) has added two innovative physical therapy devices to its pain management portfolio, acquiring the exclusive Australian and New Zealand rights to the PAINmate® and ActiPatch® brands from Evomed Pty Limited (Evomed). “Mundipharma is committed to the multimodal approach to pain management, which includes Cognitive Behavioural Therapies, Physical Therapies and Pharmacological Therapies,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “The addition of two innovative physical therapy devices to our existing pain medications reaffirms our commitment to help clinicians manage pain in a stepped, multimodal approach.” The two physical therapy devices are: PAINmate® – A portable, wireless and affordable device that sends electrical nerve stimulation through the skin to provide fast and targeted pain relief, andActiPatch® – A device that dampens the brains perception of pain my stimulating nerve activity with electromagnetic pulses. “Our pain management education programs for healthcare professionals emphasise the Quality Use of Medications and the importance of multimodal pain management, so I’m very proud that we’re now able to offer more products that support the multimodal approach,” Ms Orr said. “PAINmate® and Actipatch® are already helping many people living with pain enjoy a better quality of life and we look forward to helping even more Australians do the same.” The deal also includes exclusive Australian and New Zealand distribution rights for AccuVein®, a device that digitally displays a map of blood vessels on the surface of the skin in real time. “AccuVein® will help us deliver significant benefits for our customers and patients, as it already does in more than 100 countries and clinical settings including oncology, emergency, paediatrics, blood banks, haematology, phlebology and operating theatres to name a few.” This deal continues the growth and diversification of Mundipharma’s product portfolio, following this year’s launch of mundicare® Cold Defence, the acquisition of a prostate cancer medication and the PBS listing of a medication for Peripheral T-Cell Lymphoma.   Mundipharma’s portfolio now includes 36 effective health care products across pain, oncology, ophthalmology, respiratory, first aid, hydration and the common cold.   “Part of our growth and diversification strategy is to acquire profitable businesses and products, and this deal proves that we remain ready, willing and able to do just that,” Ms Orr said. "We will also continue to bring products to Australia and New Zealand through our global network of independent associated companies.” “This network, combined with our local autonomy and agility, is critical to our continued growth and success, and our ability to invest in long term value for our patients, customers and business partners.” About Mundipharma Mundipharma Pty Limited is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold. ®PAINMATE, ACTIPATCH and ACCUVEIN are registered trademarks. AU-4661 New natural treatment for common colds 2018-05-16T23:22:41Z new-natural-treatment-for-common-colds When taken at the first signs of a cold, mundicare® Cold Defence Nasal Spray is clinically proven to: Shorten the duration of a cold by up to 2 days1-3 It also helps: Reduce up to 99 per cent of cold viruses from the nasal lining within 3-5 days1-3 Prevent colds by forming a protective barrier in the nasal lining to trap common cold viruses, helping the body’s natural defences eliminate them Reduce the severity of common cold symptoms4-5 Thanks to its natural formulation, mundicare® Cold Defence Nasal Spray: Is preservative, steroid and medicine free Can be used during pregnancy and breastfeeding7 Antibiotic resistance is an ongoing problem in Australia GPs prescribe antibiotics at a rate up to nine times higher than the current guidelines recommend8 In a recent study more than 50 per cent of people with colds and upper respiratory tract infections were prescribed antibiotics, despite having no benefit in infections caused by viruses9 Over prescription of antibiotics can contribute to antimicrobial resistance.9 Video explaining how mundicare® Cold Defence Nasal Spray works Mundipharma has introduced a new early treatment to help families stay healthy and fight against the common cold. Common colds are viral infections that typically affect adults two to four times per year and children as often as five to 10 times each year.10 The burden of a cold can be even more pronounced in the elderly, children and those with existing illnesses or risk factors. Clinical trials including more than 350 adults and children have shown that mundicare® Cold Defence Nasal Spray reduced the duration of colds by up to two days and reduced severity of symptoms in children and adults1-3. It also led to up to 99% reduction in the amount of virus found in the nasal lining after 3-5 days1-3. The treatment contains the natural ingredient iota-carrageenan, also called Carragelose™, derived from red seaweed. It is available in adult and children’s formulations and is recommended for use at the first sign of symptoms. Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is an exciting development in the fight against the common cold.” Jane Orr, Managing Director of Mundipharma Australia and New Zealand, said “Every year the common cold puts pressure on families, drains productivity and sick leave, and interferes with daily life,” Ms Orr said. “As an early treatment to manage colds, mundicare® Cold Defence Nasal Spray can help keep families and workplaces healthy and productive.” Most existing common cold treatments only target symptoms rather than underlying infections, and many over the counter cough and cold medicines are restricted to children over six years old. mundicare® Cold Defence is preservative, steroid and medicine free. mundicare® Cold Defence can be purchased from leading pharmacies across Australia and retails for $14.95. Always read the label. Use only as directed. If symptoms persist, see your healthcare professional. About Mundipharma Mundipharma is a member of a global network of independent associated companies, which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include a range of effective products in across pain, oncology, ophthalmology, respiratory, hydration, first aid and common cold. For more information please visit: www.mundipharma.com.au. For media inquiries please contact: Rob Bates Mb. 0422 196 238 Email Rob.Bates@mundipharma.com.au For product information please contact: Joern Packross Mb. 0457 700 467 Email Joern.Packross@mundipharma.com.au References: 1. Ludwig M et al. Efficacy of a carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respiratory Research 2013;14:124. 2. Koenighofer M et al. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014;9:57. 3. Fazekas T et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complementary and Alternative Medicine 2012;12:147. 4. Eccles R et al. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebocontrolled exploratory study in volunteers with early symptoms of the common cold. Respiratory Research 2010;11:108. 5. Eccles R et al. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial. Respiratory Research 2015; 16:121. 6. MUNDICARE® COLD DEFENCE KIDS Nasal Spray Leaflet. 7. MUNDICARE® COLD DEFENCE Nasal Spray Leaflet 8. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Amanda R McCullough, Allan J Pollack, Malene Plejdrup Hansen, Paul P Glasziou, David FM Looke, Helena C Britt and Christopher B Del Mar. Medical Journal of Australia. 2017; 207 (2): 65-69. 9. Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2016: first Australian report on antimicrobial use and resistance in human health – consumer summary. Sydney: ACSQHC, 2016. 10. Healthdirect Australia ®MUNDICARE is a registered trade mark. ™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417.®MUNDICARE is a registered trade mark. ™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417. AU-4507 – 16042018 -ENDS-